Table 1 Clinical and pathological information of study cases
From: Immunohistochemical evaluation of ROCK activation in invasive breast cancer
| Â | Total | CIS | IC | ICM |
|---|---|---|---|---|
Age (years) | 53 (25, 95) | 50 (25, 77) | 54 (29, 95) | 53 (28, 87) |
Gradea | 275 | 56 | 116 | 103 |
 1 | 26 (9 %) | 13 (23 %) | 12 (10 %) | 1 (1 %) |
 2 | 172 (63 %) | 36 (64 %) | 74 (64 %) | 62 (60 %) |
 3 | 77 (28 %) | 7 (13 %) | 30 (26 %) | 40 (39 %) |
ER | 266 | 54 | 111 | 101 |
 Negative | 88 (33 %) | 7 (13 %) | 37 (33 %) | 44 (44 %) |
 Positive | 178 (67 %) | 47 (87 %) | 74 (67 %) | 57 (56 %) |
PR | 265 | 54 | 111 | 100 |
 Negative | 126 (48 %) | 14 (26 %) | 55 (50 %) | 57 (57 %) |
 Positive | 139 (52 %) | 40 (74 %) | 56 (50 %) | 43 (43 %) |
HER2 | 264 | 53 | 109 | 102 |
 Negative | 199 (72 %) | 45 (85 %) | 84 (77 %) | 70 (69 %) |
 Positive | 65 (25 %) | 8 (15 %) | 25 (23 %) | 32 (31 %) |
Follow up (months) | 108 (1, 262) | 97 (1, 213) | 132 (9, 262) | 86 (1, 257) |